Skip to main content

Bausch Health Companies Inc. Value Stock - Dividend - Research Selection

Bausch health

ISIN: CA0717341071 , WKN: A2JQ1X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company is engaged in the development and commercialization of a range of generics, generic and branded products, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgery devices and aesthetic devices). It operates through two segments: developed markets and emerging markets. The Developed Markets segment focuses on the areas of dermatology, neurology, gastrointestinal diseases and ophthalmology. The Emerging Markets segment focuses primarily on branded generics, OTC products and medical devices. The pharmaceutical products include Xifaxan, Solodyn and Glumetza. OTC products include Preservision, Biotrue and Boston. Other generics include latanoprost and metronidazole. The ophthalmic products include intraocular lenses such as Akreos, enVista, Crystalens and Trulign.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down

2026-01-27
Bausch Health shares slide after late-stage RED-C trials for rifaximin SSD fail, derailing plans to expand Xifaxan's cirrhosis-related use.

Bausch Health’s new formulation of Xifaxan fails pair of Phase III trials

2026-01-26
Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap the molecule’s development.

Down 17.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Bausch (BHC)

2026-01-26
Bausch (BHC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

What Could Reset The Story For Bausch Health Companies (BHC) After New Analyst Target

2026-01-25
Analysts have recently reset their price target on Bausch Health Companies, signalling a meaningful shift in how the stock is being framed and discussed. With no prior target to compare against, this new figure effectively becomes a fresh reference point for how the market may think about the company. Stay tuned, because the rest of this article will show you how to keep on top of these kinds of narrative changes as they develop. Analyst Price Targets don't always capture the full story. Head...

TSX Closer: Sets Ninth Record Close of 2026; Rosenberg On 'Why Consumer Staples Look Interesting Again'

2026-01-23
The Toronto Stock Exchange set its ninth record close of 2026 on Friday, buoyed by elevated commodit

Sector Update: Health Care Stocks Softer Late Afternoon

2026-01-23
Health care stocks declined late Friday afternoon, with the NYSE Health Care Index and the State Str

Truist Says RED-C Failure "Adds Further Pressure" on the Bausch Health Franchise; BHC Down 10% In Canada

2026-01-23
The Ph3 results of the RED-C program announced earlier Friday by Bausch Health (BHC.TO, BHC) "could

TSX up 93 Points at Midday With Info Tech, Commodities, The Best Performers

2026-01-23
The Toronto Stock Exchange is up 93 points at midday with most sectors higher. The best performer

Bausch Health: RED-C Failure Leaves Blockbuster Xifaxan Without A Successor

2026-01-23
Bausch Health Companies Inc. was hit by a failed RED-C Phase 3, weak cash flow vs. interest, and a risky pipeline. Click for more on BHC stock as it sells off.

Bausch Health Provides Update on RED-C Phase 3 Clinical Trials

2026-01-23
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy (HE). While safe and well-tolerated, both clinical trials did not meet the primary endpoint.